Injectable GLP-1 RAs like liraglutide, semaglutide, and dulaglutide have been shown to significantly lower HbA1c and body weight in patients with T2DM
On March 5, Novo Nordisk released the top-line results from this pivotal kidney outcomes trial: Use of semaglutide in patients with diabetic kidney disease reduced the primary outcomea composite of kidney failure, 50% decline in estimated glomerular filtration rate (eGFR), and cardiovascular (CV) or kidney deathby an impressive 24% (Figure 1)
Always consult with your GP or pharmacist before combining medications
The more holes and the larger the size of the holes, the quicker will the fat be removed
Rachot Vachathrone, MD , at Medallus Urgent Care offers transparent pricing for IV therapy, ensuring that patients are fully informed before receiving treatment
A phase 2 trial studied exenatide usage on intracranial pressure (ICP) in patients with IIH over 12 weeks